The purpose of this study to preliminarily evaluate the safety and efficacy of High Efficient Killing Cell Therapy for refractory and advanced non-small cell lung cancer
Eligibility
Sex
ALL
Min age
18 Years
Max age
70 Years
Healthy volunteers
No
Inclusion Criteria:
* Male or female patients' age from 18 years to 70 years.
* Patients who have a life expectancy of at least 3 months.
* pathologically confirmed non-small cell lung cancer.
* failed in previous standard chemotherapy and targeted therapy.
* Karnofsky performance status 0-1.
* adequate organ functions.
Exclusion Criteria:
* Pregnant and lactating women.
* Patients with T cell lymphoma, syphilis, AIDS or combination
* Patients with highly allergic or have a history of severe allergies
* Patients with severe hepatic or renal dysfunction
* Patients with severe autoimmune disease or who is being treated with immunosuppressive agents
* Patients with severe infection not controlled or High fever
* Patients with organ transplantation or waiting for organ transplantation.
* Patients with brain metastasis
* Patients with severe coagulopathy (e.g. hemophilia)
* Patients without adequate ability to understand, sign informed consents and take part in the clinical research voluntarily.
Primary outcome measure(s)
safety:safety index of blood, heart, lung, kidney and brain function damaged mainly during the treatment — 2 years Occurrence of study related adverse events as assessed by CTCAE v4.0
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time on our Cookie Policy page. See also our Privacy Policy.